LSE to delist Ranbaxy GDR programme with effect from Dec 15

Drug firm Ranbaxy Laboratories today said Luxembourg Stock Exchange (LSE) will delist the company's Global Depository Receipts programme with effect from December 15.

In view of the proposed termination of the deposit agreement on December 15, 2014, the LSE will de-list the GDS from the official list and withdraw the trading of GDS on the Euro MTF Market of the LSE with effect from December 15, 2014, Ranbaxy Laboratories Ltd said in a filing to the BSE.

The company said it has received a letter from LSE in this regard.

Earlier this month, the company had said that it has notified the Bank of New York Mellon to terminate the Deposit Agreements dated July 7, 1994 and underlying Global Depository Receipts (GDR) programme.
 

Ranbaxy shares today closed at Rs 632.10 apiece on the BSE, up 1.34 per cent from their previous close.